RNA-LNP Therapeutics Startup Axelyf Seeded to Conquer Delivery Challenges
Former Moderna executive Örn Almarsson aims to expand RNA therapeutic targets using proprietary lipid chemistry and AI.
🧬 We are proud to announce our latest investment in Axelyf’s seed financing round, supporting their mission to advance next-generation RNA-LNP therapeutics.
“We’re not chasing science fiction, we’re contributing real solutions for tackling complex diseases,” said Örn Almarsson, PhD, CEO and co-founder of Axelyf, who previously led drug delivery efforts at Moderna during COVID-19 vaccine and therapeutics development.
As highlighted in Inside Precision Medicine, Axelyf is tackling one of the biggest challenges in RNA therapeutics: safe and effective delivery. Their proprietary technology, combined with assets acquired from 76Bio, Inc., enables superior potency, biodegradability, and extrahepatic delivery capabilities.
Other investors include Omega VC and Silfurberg.
“The company is a rare combination of cutting-edge science, proven leadership, and IP strength. This team can deliver on RNA medicine’s promise, and we are excited to be part of the journey,” said Arni Blöndal, Founding Partner at Brunnur Ventures, who joins Axelyf’s Board of Directors.
📖 Read the full release 👉 https://www.insideprecisionmedicine.com/topics/translational-research/rna-lnp-therapeutics-startup-axelyf-seeded-to-conquer-delivery-challenges/